aTyr Pharma, Inc., headquartered in San Diego and founded in 2015, focuses on developing medicines by exploring the novel biological pathways of tRNA synthetases. Their main product, efzofitimod, aims to treat pulmonary sarcoidosis by targeting neuropilin-2 to alleviate chronic inflammation and fibrosis.
Atyr Pharma (ATYR) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Atyr Pharma's actual EPS was -$0.23, beating the estimate of -$0.24 per share, resulting in a 5.27% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
